Home » Stocks » Natera

Natera, Inc. (NTRA)

Stock Price: $51.04 USD -0.29 (-0.56%)
Updated Aug 11, 2020 2:51 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 4.08B
Revenue (ttm) 341.63M
Net Income (ttm) -153.33M
Shares Out 79.72M
EPS (ttm) -2.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $51.04
Previous Close $51.33
Change ($) -0.29
Change (%) -0.56%
Day's Open 51.19
Day's Range 49.16 - 52.10
Day's Volume 289,077
52-Week Range 16.87 - 56.51

More Stats

Market Cap 4.08B
Enterprise Value 3.78B
Earnings Date (est) Nov 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 79.72M
Float 76.32M
EPS (basic) -1.99
EPS (diluted) -2.01
FCF / Share -1.48
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5.86M
Short Ratio 7.43
Short % of Float 8.46%
Beta 1.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 11.94
PB Ratio 14.45
Revenue 341.63M
Operating Income -142.44M
Net Income -153.33M
Free Cash Flow -117.27M
Net Cash 300.59M
Net Cash / Share 3.76
Gross Margin 37.13%
Operating Margin -41.69%
Profit Margin -44.90%
FCF Margin -34.33%
ROA -17.51%
ROE -77.18%
ROIC -27.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (6)

Buy 5
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$62.33*
(22.12% upside)
Low
60.0
Current: $51.04
High
66.0
Target: 62.33
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013
Revenue30225821021319015955.17
Revenue Growth17.34%22.91%-1.36%11.64%19.5%188.72%-
Gross Profit12791.6070.0376.9477.5180.8917.90
Operating Income-116-115-135-101-59.840.67-25.27
Net Income-125-128-138-100-70.28-5.15-37.11
Shares Outstanding69.5657.8553.3151.5826.204.803.84
Earnings Per Share-1.79-2.22-2.59-1.95-2.68-1.07-9.66
Operating Cash Flow-63.44-70.58-97.83-74.05-37.8310.49-24.13
Capital Expenditures-4.97-3.88-9.87-23.14-7.39-9.94-8.25
Free Cash Flow-68.41-74.46-108-97.19-45.220.55-32.38
Cash & Equivalents44115411914623187.1831.39
Total Debt15012412349.6242.0926.8124.31
Net Cash / Debt29130.36-4.3196.4918860.367.09
Assets58326821521126512459.72
Liabilities30423618910480.4854.3546.03
Book Value27932.1625.42106185-171-172
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Natera, Inc.
Country United States
Employees 1,039
CEO Stephen Chapman

Stock Information

Ticker Symbol NTRA
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: NTRA
IPO Date July 2, 2015

Description

Natera, Inc. provides preconception and prenatal genetic testing services. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora products of conception test to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother's blood and a blood sample from the alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Evercord, a cord blood and cord tissue processing and storage service; and Signatera, a circulating tumor DNA technology that analyzes and tracks mutations to an individual's tumor. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners in the United States and internationally. Natera, Inc. has research collaborations with the Institut Jules Bordet and Fox Chase Cancer Center; and a partnership agreement with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays for use by biopharmaceutical and clinical customers. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.